SecProbe.io

Filing text and metadata
Intelligence Terminal Search Topics Monthly Activity About

UPLOAD Filing

ALT5 Sigma Corp
Date: Sept. 18, 2025 · CIK: 0000862861 · Accession: 0000000000-25-010201

AI Filing Summary & Sentiment

Sentiment
Urgency
Document Type
Confidence
SEC Posture
Company Posture

Summary

Reasoning

File numbers found in text: 000-19621

Date
September 18, 2025
Author
Finance
Form
UPLOAD
Company
ALT5 Sigma Corp

Letter

Re: ALT5 Sigma Corporation Preliminary Proxy Statement on Schedule 14A Filed September 12, 2025 File No. 000-19621 Dear Jonathan Hugh:

September 18, 2025

Jonathan Hugh Chief Financial Officer ALT5 Sigma Corporation 325 E. Warm Springs Road, Suite 102 Las Vegas, Nevada 89119

We have reviewed your filing and have the following comments.

Please respond to this letter within ten business days by providing the requested information or advise us as soon as possible when you will respond. If you do not believe a comment applies to your facts and circumstances, please tell us why in your response.

After reviewing your response and any amendment you may file in response to this letter, we may have additional comments.

Preliminary Proxy Statement on Schedule 14A Proposal 1 The Issuance and Appointment Proposal, page 7

1. We refer to Proposal 1, which seeks shareholder approval for (i) the issuance of 119,000,000 shares of common stock upon the exercise of pre-funded warrants and common stock purchase warrants, and (ii) the appointment of a nominee to the board of directors. Please tell us why these two matters should not be in separate proposals. Refer to Rule 14a-4(a)(3). 2. We note that the appointment of the director to the board appears to be an action taken with respect to the election of a director. Accordingly, please revise the proxy to include all information required by Items 7 and 8 of Schedule 14A, or advise. We remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff. September 18, 2025 Page 2

Please contact Jimmy McNamara at 202-551-7349 or Joe McCann at 202-551-6262 with any other questions.

Sincerely,
Division of Corporation
Finance
Office of Life Sciences
cc: Faith Charles

Show Raw Text
<DOCUMENT>
<TYPE>TEXT-EXTRACT
<SEQUENCE>2
<FILENAME>filename2.txt
<TEXT>
 September 18, 2025

Jonathan Hugh
Chief Financial Officer
ALT5 Sigma Corporation
325 E. Warm Springs Road, Suite 102
Las Vegas, Nevada 89119

 Re: ALT5 Sigma Corporation
 Preliminary Proxy Statement on Schedule 14A
 Filed September 12, 2025
 File No. 000-19621
Dear Jonathan Hugh:

 We have reviewed your filing and have the following comments.

 Please respond to this letter within ten business days by providing the
requested
information or advise us as soon as possible when you will respond. If you do
not believe a
comment applies to your facts and circumstances, please tell us why in your
response.

 After reviewing your response and any amendment you may file in
response to this
letter, we may have additional comments.

Preliminary Proxy Statement on Schedule 14A
Proposal 1
The Issuance and Appointment Proposal, page 7

1. We refer to Proposal 1, which seeks shareholder approval for (i) the
issuance of
 119,000,000 shares of common stock upon the exercise of pre-funded
warrants and
 common stock purchase warrants, and (ii) the appointment of a nominee to
the board
 of directors. Please tell us why these two matters should not be in
separate
 proposals. Refer to Rule 14a-4(a)(3).
2. We note that the appointment of the director to the board appears to be
an action taken
 with respect to the election of a director. Accordingly, please revise
the proxy to
 include all information required by Items 7 and 8 of Schedule 14A, or
advise.
 We remind you that the company and its management are responsible for
the accuracy
and adequacy of their disclosures, notwithstanding any review, comments, action
or absence
of action by the staff.
 September 18, 2025
Page 2

 Please contact Jimmy McNamara at 202-551-7349 or Joe McCann at
202-551-6262
with any other questions.

 Sincerely,

 Division of Corporation
Finance
 Office of Life Sciences
cc: Faith Charles
</TEXT>
</DOCUMENT>